TABLE 1.
| IPF (n=38) | SSc (n=15) | p-value | |
|---|---|---|---|
| Baseline Demographic | |||
| Female Gender, n (%) | 9 (24%) | 4 (29%) | 0.73 |
| Limited Disease, n (%) | - | 11 (79%) | - |
| Age, years | 58.8 (53.6–62.3) | 53.2 (42.6–58) | 0.02* |
| Patient followup days | 788 (550–950) | 632 (442–1033) | 0.99 |
| DeMeester Score | - | 42.6 (32.3–52.7) | - |
| Mean RA pretransplant | 6.03 (4.0–8.0) | 7.07 (2.0–10) | 0.90 |
| Mean PAP pretransplant | 23.5 (20–32.5) | 29 (23–45) | 0.11 |
| CO pretransplant | 5.31 (4.47–6.0) | 4.83 (4.2–5.6) | 0.30 |
| Echo RVSP | 51 (37–62) | 61 (40–82) | 0.43 |
| Lung Allocation Score | 42.5 (36.7–45.3) | 42 (35.9–46.7) | 0.98 |
| # Bronchoscopies | 5 (4–6) | 6 (4–7.5) | 0.19 |
| T72 PGD 2–3 | 8 (21%) | 3 (20%) | 1 |
| T72 PGD 3 | 4 (11%) | 2 (13%) | 1 |
| Donor Ischemia, minutes | 334+/−60 | 354+/−68 | 0.34 |
| CPB time, minutes | 199+/−38 | 217+/−55 | 0.26 |
| CMV status | - | - | 0.81 |
| Lung Function (12 mo) | |||
| FEV1 (% predicted) | 77 (69.5–85.5) | 74.5 (65.5–99.5) | 1 |
| FVC (% predicted) | 73 (63.5–80) | 68.5 (58–99) | 0.85 |
| FEV1/FVC (%) | 80 (73–86) | 83 (76–84.5) | 0.93 |
| Renal Function | |||
| Creatinine Clearance (pre transplant) | - | 92.2 (64.8–118) | - |
| Creatinine Clearance (12 mo) | - | 63.2 (55.5–78.5) | - |
| Survival | |||
| # Deaths at 12 months | 5 | 1 | 0.53 |
*
p value is statistically significant by t-test, Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test.
All values are median (25th–75th percentile) unless otherwise stated.
Patient follow up days (mean ± SD).
PAP (mean pulmonary artery pressure); RA (right atrial pressure); CO (cardiac output); RVSP (right ventricular systolic pressure); T72 PGD 2–3 (primary graft dysfunction grade 2 or 3 at 72 hours post lung transplant); CPB (cardiopulmonary bypass); CMV (cytomegalovirus) status includes the four potential combinations of donor and recipient CMV status